[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Vivani Medical, Inc\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":47},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":4},"100626009","phase-1-safety-tolerability-and-pharmacokinetics-of-a-subcutaneous-semaglutide-implant-100626009",false,"NCT07430059","Safety, Tolerability and Pharmacokinetics of a Subcutaneous Semaglutide Implant","A Randomized, Parallel-Group Study to Assess the Safety, Tolerability, and Pharmacokinetics of Semaglutide Implant","SLIM-1","Inclusion Criteria:\n\n* BMI between 27 and 40 kg\u002Fm2 (inclusive)\n* HbA1c \\\u003C\u002F= 6.0% and FPG \\\u003C\u002F+ 6.7 mmil\u002FL\n* eGFR \\>\u002F= 60 mL\u002Fm2\n* No significant health issues in the opinion of the Investigator that would preclude study participation, as determined by medical history and physical examination\n\nExclusion Criteria:\n\n* Type 1 or Type 2 Diabetesa\n* A clinically significant medical condition that could potentially affect study participation and\u002For personal well-being, as judged by the Investigator\n* Treatment with glucose lowering agent(s) within 3 months before Screening","ALL","18 Years","60 Years",{"count":21,"type":22},20,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","The study will evaluate the safety, tolerability and drug levels of a semaglutide implant placed just under the skin for a period of 4 weeks compared to 4 weekly injections of semaglutide (Wegovy) in overweight\u002Fobese participants who are otherwise healthy..",[28],"Obesity & Overweight",[30,31,32,33,34],"obesity","overweight","semaglutide","implant","glp-1","NOT_YET_RECRUITING","2026-06-25",{"date":38,"type":39},"2026-06-30","ACTUAL",{"date":41,"type":22},"2026-07",{"date":43,"type":22},"2027-01",{"name":45,"class":46},"Vivani Medical, Inc","INDUSTRY",""]